➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKesson
Dow
Moodys
Express Scripts
Merck

Last Updated: January 18, 2021

DrugPatentWatch Database Preview

Litigation Details for Quest Diagnostics Incorporated v. Myriad Genetics, Inc. (C.D. Cal. 2013)

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Quest Diagnostics Incorporated v. Myriad Genetics, Inc. (C.D. Cal. 2013)

Docket   Start Trial Date Filed 2013-10-10
Court District Court, C.D. California Date Terminated 2014-03-03
Cause 28:2201 Declaratory Judgment Assigned To Andrew J. Guilford
Jury Demand Plaintiff Referred To Douglas F. McCormick
Parties MYRIAD GENETICS, INC.; QUEST DIAGNOSTICS INCORPORATED; QUEST DIAGNOSTICS NICHOLS INSTITUTE
Patents 6,051,379; 6,083,698
Attorneys David Martinez; Emmett J McMahon; Geoffrey D Biegler; Jonathan E Singer; Limin Zheng; Martin R Lueck; Matfhew B McFarlane; Rebecca Shult
Firms Fish & Richardson; Fish & Richardson Pc; Fish and Richardson PC; Robins Kaplan LLP; Robins Kaplan Miller & Ciresi LLP; Robins Kaplan Miller and Ciresi LLP
Link to Docket External link to docket
Biologic Drugs cited in Quest Diagnostics Incorporated v. Myriad Genetics, Inc.
The biologic drug covered by the patents cited in this case is   Start Trial .

Details for Quest Diagnostics Incorporated v. Myriad Genetics, Inc. (C.D. Cal. 2013)

Date Filed Document No. Description Snippet Link To Document
2013-10-10 1 and 6,051,379 (together, the “patents-in-suit”) 11 and that each and every claim of the patents-in-suit…34. U.S. Patent No. 6,051,379 (“the ’379 patent”), titled “CANCER 7 SUSCEPTIBILITY MUTATIONS OF … THE PATENTS IN SUIT 2 8. U.S. Patent No. 5,747,282 (“the ’282 patent”), titled “17Q-LINKED…claims from the patents-in-suit: 18 claim 1 of the ‘999 patent, claim 1 of the ‘441 patent, claims 1 and… ’282 patent, and 6 Myriad has asserted that it has the sole right to enforce the ’282 patent. 7 External link to document
2013-11-25 24 28 6,951,721; 6,492,109; and 6,051,379 (together, the “patents-in-suit”). …Finally, this Court’s local patent rules, participation in the 19 Patent Pilot Program, and its much…exclusive licensee of numerous patents, 24 including the fourteen patents-in-suit,1 related to two human…invalidity of the following 27 fourteen patents: U.S. Patent Nos. 5,747,282; 5,693,473; 5,709,999; 5,… 5 enforcement of its BRCA1/2 patent estate, including the patents previously before 6 the Supreme External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Medtronic
Mallinckrodt
Colorcon
Express Scripts
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.